Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

Date publication

juin 2022

Journal

European urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35750582

Résumé

Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations.

Mots clés

BRCA1/2 status, Brief Pain Inventory, DNA damage response alteration, Metastatic castration-resistant prostate cancer, Patient-reported outcomes, Poly(ADP-ribose) polymerase inhibitor, TALAPRO-1 trial, Talazoparib

Référence

Eur Urol. 2022 06 21;: